Abstract
In a placebo-controlled, double-blind, randomized, parallel group study one hundred and one patients with supine diastolic blood pressure greater than or equal to 100 mm Hg phase V, despite treatment with atenolol 100 mg plus chlorthalidone 25 mg once daily also received either felodipine 5-20 mg twice daily or hydralazine 25-100 mg twice daily for 6 weeks. Felodipine achieved a lower supine blood pressure (mean +/- s.d. 177/108 +/- 29/8-138/82 +/- 19/8 mm Hg) than hydralazine (174/109 +/- 25/8-149/92 +/- 26/11 mm Hg), (P less than 0.05/P less than 0.001). Felodipine also lowered supine diastolic blood pressure to less than 90 mm Hg more often than hydralazine (42 vs 22 patients, P less than 0.001). The incidence of unwanted effects was similar in both groups. The felodipine treated patients experienced more ankle swelling and flushing than those in the hydralazine group who experienced more headache and minor gastro-intestinal upset.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bing R. F., Russell G. I., Thurston H., Swales J. D. Hydrallazine in hypertension: is there a safe dose? Br Med J. 1980 Aug 2;281(6236):353–354. doi: 10.1136/bmj.281.6236.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cameron H. A., Ramsay L. E. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J (Clin Res Ed) 1984 Aug 18;289(6442):410–412. doi: 10.1136/bmj.289.6442.410. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Collste P., Danielsson M., Elmfeldt D., Feleke E., Gelin A., Hedner T., Rydén L. Long term experience of felodipine in combination with beta-blockade and diuretics in refractory hypertension. Drugs. 1985;29 (Suppl 2):124–130. doi: 10.2165/00003495-198500292-00022. [DOI] [PubMed] [Google Scholar]
- Culling W., Ruttley M. S., Sheridan D. J. Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease. Br Heart J. 1984 Oct;52(4):431–434. doi: 10.1136/hrt.52.4.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Elmfeldt D., Hedner T. Antihypertensive effects of felodipine compared with placebo. Drugs. 1985;29 (Suppl 2):109–116. doi: 10.2165/00003495-198500292-00020. [DOI] [PubMed] [Google Scholar]
- Elmfeldt D., Hedner T. Felodipine--a new vasodilator, in addition to beta-receptor blockade in hypertension. Eur J Clin Pharmacol. 1983;25(5):571–575. doi: 10.1007/BF00542340. [DOI] [PubMed] [Google Scholar]
- Ljung B. Vascular selectivity of felodipine. Drugs. 1985;29 (Suppl 2):46–58. doi: 10.2165/00003495-198500292-00011. [DOI] [PubMed] [Google Scholar]
- McAreavey D., Ramsey L. E., Latham L., McLaren A. D., Lorimer A. R., Reid J. L., Robertson J. I., Robertson M. P., Weir R. J. "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. Br Med J (Clin Res Ed) 1984 Jan 14;288(6411):106–111. doi: 10.1136/bmj.288.6411.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Murphy M. B., Scriven A. J., Dollery C. T. Role of nifedipine in treatment of hypertension. Br Med J (Clin Res Ed) 1983 Jul 23;287(6387):257–259. doi: 10.1136/bmj.287.6387.257. [DOI] [PMC free article] [PubMed] [Google Scholar]